Bills Address Women's Health and Cancer Issues

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

WASHINGTON--Cancer ranked high among a package of seven Senate bills introduced by Sen. Olympia Snowe (R-Maine), all of them intended to address women's health issues.

WASHINGTON--Cancer ranked high among a package of seven Senate billsintroduced by Sen. Olympia Snowe (R-Maine), all of them intended to addresswomen's health issues.

The "Consumer Involvement in Breast Cancer Act" would requirethe National Institutes of Health to include breast cancer advocates inits decision-making on breast cancer research.

Under the "Breast Cancer Screening Act of 1997," the NationalCancer Institute would have to reissue the mammog-raphy guidelines forwomen in their 40s that it dropped in 1993.

The "Breast Cancer Research Extension Act of 1997" would increasethe funding authorization for breast cancer research in fiscal year 1998,which begins Oct. 1, by $59 million, to a total of $590 million.

In addition, Sen. Snowe's "One-Stop Shopping Information Service"bill, co-introduced by Sen. Diane Feinstein (D-Calif), would require thesecretary of Health and Human Services to establish a database of all publicand private clinical trials in the United States that patients with life-threateningillnesses could access via a toll-free telephone number.

Recent Videos
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Related Content